| Document |
Document Title |
|
WO/2019/197239A1 |
The present invention provides methods for the preparation of Compound (I): Compound (I), the use of intermediates for the preparation of said compound and its crystalline form A.
|
|
WO/2019/192246A1 |
Disclosed by the present invention is a novel crystal form of prothioconazole — a crystal toluene solvate of the prothioconazole; the new compounds are generally more stable than an amorphous compound, such that they can be used for lo...
|
|
WO/2019/194220A1 |
Provided are compounds represented by formula (1) or salts thereof, and a pest control agent, an insecticide or miticide, a nematicide, and an endoparasite control or eliminating agent, which contain, as an active ingredient, at least on...
|
|
WO/2019/193342A1 |
The present invention relates to compounds as defined herein, which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to therapies using these activators. In particular, the invention relates...
|
|
WO/2019/191502A1 |
This disclosure concerns compounds and a method for modulating the activity of calcium ion channels, including Ca2+-induced (or Ca2+-activated) calcium release channels and conformationally coupled calcium release channels such as ryanod...
|
|
WO/2019/184772A1 |
The present invention discloses a gibberellin-like compound, a preparation method therefor, a pharmaceutical composition, uses and an intermediate thereof, wherein the gibberellin-like compound shown in formula (I) has relatively good in...
|
|
WO/2019/182743A1 |
The instant invention describes pharmaceutical compositions and dosing regimens comprising seviteronel and/or dexamethasone, and methods of treating diseases, disorders symptoms thereof.
|
|
WO/2019/180646A1 |
The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their...
|
|
WO/2019/180644A1 |
The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or hete...
|
|
WO/2019/174974A1 |
The invention relates to a fertilizer composition comprising a) zeolitic imidazolate framework ZIF-8; and b) a fertilizer selected from liquid or solid ammonium-containing inorganic fertilizers, liquid or solid organic fertilizers, and u...
|
|
WO/2019/174977A1 |
The invention relates to a composition comprising a) zeolitic imidazolate framework ZIF-8; and b) Compounds of formula (I) or a stereoisomer, salt, tautomer or N-oxide thereof, wherein the variables have a meaning as defined in the main ...
|
|
WO/2019/178305A1 |
The present invention is directed to new pyridinone or pyrimidinone hydroxamic acid phosphates of Formula (1 ) and boronates of Formula (2), stereoisomers thereof; wherein Q is selected from the group consisting of -P(0)(OH)2, -P(0)(OH)(...
|
|
WO/2019/171161A1 |
PCT00760 20 ABSTRACT Disclosed herein is a process for preparation of 1-chloro-2-(1- chlorocyclopropyl)-3-(2-chlorophenyl)propan-2-ol (compound of formula (I)) 5 and 2-(1-chlorocyclopropyl)-2-[(2-chlorophenyl)methyl]oxirane (compound of ...
|
|
WO/2019/170946A1 |
The invention describes a new general method for the aerobic rupture or oxidation of compounds having a tertiary carbon directly bonded to an aryl group, and polymers based on said structural monomeric unit, to provide the corresponding ...
|
|
WO/2019/171160A1 |
The present invention relates to a process for the preparation of fungicidally active triazole compounds wherein said process uses homologous cage amines as the catalyst.
|
|
WO/2019/171088A1 |
The present invention relates to novel bio-inspired hybrid compounds of formula I which act as proteasome activators and exhibit anti-ageing activity, as well as methods for their synthesis. These hybrid compounds combine the structural ...
|
|
WO/2019/169333A1 |
Described herein are compounds of Formula (I), modified polymers and implantable elements comprising compounds of Formula (II), as well as compositions and methods of use thereof. In particular, the compounds, modified polymers, implanta...
|
|
WO/2019/169193A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ recep...
|
|
WO/2019/168842A1 |
Provided herein are novel amide prodrug forms of pharmaceutically active agents useful for central nervous system disorders.
|
|
WO/2019/166537A1 |
The present invention describes novel chelators (multidentate ligands) and precompounds for complexation of radiometals and non-radioactive counterparts, for use in radiopharmacy. The invention includes a process and a kit involving such...
|
|
WO/2019/162309A1 |
The present invention relates to benzamide compounds of formula I (I) wherein the variables are defined as in the claims and the description, the N-oxides and salts thereof,and to compositions comprising the same. The invention also rela...
|
|
WO/2019/165159A1 |
Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need t...
|
|
WO/2019/157417A1 |
Disclosed are compounds of formulas (I)-(IX) for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, wherein R1-R8, X, Y, Z, X', Y', Z', and A are as defined her...
|
|
WO/2019/150138A1 |
The present invention relates to covalently bonded conjugates of cyclodextrins and deferasirox or an analogue thereof, pharmaceutical compositions comprising such conjugates and methods to make such conjugates. The conjugates may be usef...
|
|
WO/2019/149090A1 |
The present invention provides a crystal form of a urate transporter 1 inhibitor and a preparation method and use thereof. The crystal form is characterized by stable apparent condition, capability of further improving the purity of the ...
|
|
WO/2019/149091A1 |
The present invention relates to the field of compounds, and in particular to a probucol derivative, a preparation method therefor and use thereof, the probucol derivative having a structure represented by general formula I. The probucol...
|
|
WO/2019/147899A1 |
A method to induce photo-chemical reactions in a nanoscale space is provided. The method includes fixing cells and incubating the cells with a probe containing a tag for a click reaction. The probe is a psoralen probe that includes an al...
|
|
WO/2019/147987A1 |
This invention is directed to antimicrobial compositions and methods of using the same to treat or prevent infection. A method of treating microbial infection in a subject, the method comprising administering to the subject a therapeutic...
|
|
WO/2019/141230A1 |
Disclosed are processes for the synthesis of sulfentrazone, which provide a high conversion of sulfentrazone amine and high yield of the final sulfentrazone product.
|
|
WO/2019/142192A1 |
Novel compounds capable of inhibiting methionine metabolic pathway are provided. These compounds are used in inhibiting cystathionin γ-synthase (CGS) in general, and in plants, fungi and bacteria, in particular. These compounds of the i...
|
|
WO/2019/139065A1 |
An organic EL element having at least a positive electrode, a hole transport layer, a light-emitting layer, an electron transport layer, a negative electrode, and a capping layer in the stated order, wherein the capping layer contains an...
|
|
WO/2019/134993A1 |
The present invention relates to benzamide compounds of formula (I), the N-oxides and the salts thereof (I), where the variables are as defined in the claims and the description. The invention also relates to compositions comprising such...
|
|
WO/2019/135975A1 |
The invention relates to compounds, methods and compositions for improving on nucleic acid polymerization, including DNA replication by in vitro primer extension to generate, for example, polymers for nanopore-based single molecule seque...
|
|
WO/2019/133770A2 |
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the en...
|
|
WO/2019/126090A1 |
The present invention provides compounds of Formula (I): Formula (I), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA...
|
|
WO/2019/123368A1 |
The present invention relates to an improved and efficient process for the synthesis of 2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropy
l]-2,4-dihydro-3H-1,2,4- triazole-3-thione, compound of formula (I) (Prothioconazole). T...
|
|
WO/2019/121133A1 |
The present invention relates to a method of preparing 4-aryl-1,2,4- triazolidine-3,5-dione of the formula (I) and 4-aryl-1,2,4-triazole-3,5-dione of the formula (VII). This method is particularly suitable as the synthesis of 4-aryl-1,2,...
|
|
WO/2019/124577A1 |
The present invention relates to a novel triazole derivative and a salt thereof. A triazole derivative or a salt thereof according to the present invention induces or promotes browning of white adipocytes and differentiates stem cells, e...
|
|
WO/2019/125785A1 |
A catalytically active substance includes a copper (I) sulfide mineral particle, and an alkyne functionalized molecule bound to a surface of the copper (I) sulfide mineral particle. In an example method, a copper (I) sulfide mineral is r...
|
|
WO/2019/122345A1 |
The present invention relates to benzamide compounds of formula I wherein the variables are defined as in the claims and the description, the N-oxides and salts thereof,and to compositions comprising the same. The invention also relates ...
|
|
WO/2019/114838A1 |
Disclosed are a crystal of a 4-(naphthalen-1-yl)-4H-1,2,4-triazole compound (1) and a preparation method therefor, also comprised are applications of the crystal in preparing a medicament for treating an abnormal uric acid level-related ...
|
|
WO/2019/113301A1 |
The instant invention describes pharmaceutical compositions and dosing regimens comprising seviteronel and/or dexamethasone, and methods of treating diseases, disorders or symptoms thereof.
|
|
WO/2019/109415A1 |
The present invention provides a compound that is a compound represented by formula I or its stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug: X-Y-Z Formu...
|
|
WO/2019/109099A1 |
The present disclosure is directed to asymmetric triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also di...
|
|
WO/2019/106621A1 |
The present invention provides the process for the preparation of Roxadustat and its intermediates. Another aspect of the present invention provides a process for preparation of ethyl-5-(2-butoxycarbonyl)-4-phenoxyphenyl) oxazole-4-carbo...
|
|
WO/2019/108800A1 |
The invention relates to compounds that promote hematopoietic regeneration. The invention further relates to methods of promoting hematopoietic regeneration using the novel compounds of the invention.
|
|
WO/2019/107386A1 |
The present invention provides a method for enhancing an antitumor effect by a compound that strongly inhibits ribonucleotide reductase (RNR) or a salt of said compound. A combination formulation in which a sulfonamide compound that has ...
|
|
WO/2019/096884A1 |
The invention relates to benzoyl amides of general formula (I), as herbicides. In formula (I), B is N or CH, and X1 and X2 are O or S(O)n. R, Ra and Rb are groups such as hydrogen, halogen, (C1-C6)-alkyl, halogen-(C1-C6)-alkyl, (C1-C6)-a...
|
|
WO/2019/095891A1 |
The present invention provides a tebuconazole polymorph and a preparation method therefor. In particular, the present invention relates to a polymorph of (RS)-1-(4-chlorophenyl)-4,4-dimethyl-3-(1H-1,2,4-triazol-1-y
lmethyl)pentan-3-ol, a...
|
|
WO/2019/093522A1 |
Provided is a plant disease control agent which has low toxicity to humans and animals, while having excellent safety in handling, and which exhibits excellent controlling effect on a wide range of plant diseases and high antibacterial a...
|
